Venous Thromboembolism Prophylaxis

Introduction to UFH Prophylaxis

• The standard starting dose for subcutaneous unfractionated heparin (UFH) for VTE prophylaxis is 5000 units administered every 8 hours (three times daily), as recommended by the National Comprehensive Cancer Network and the American College of Cardiology 1, 2
• This three-times-daily regimen is more effective than twice-daily dosing in preventing DVT in general surgery patients, according to the National Comprehensive Cancer Network and supported by the American College of Cardiology 1, 2

Dosing Regimens

• The standard prophylactic dose is 5000 units subcutaneously every 8 hours, as stated by the National Comprehensive Cancer Network and the American College of Cardiology 1, 2
• Alternative dosing regimens include 5000 units every 12 hours, although this appears less effective, particularly in oncologic surgery, as reported in the Journal of Clinical Oncology 3
• Dosing varies by trimester during pregnancy:
• Postpartum: 5000 units subcutaneously every 8-12 hours, as recommended by the American College of Obstetricians and Gynecologists 4

Special Populations

• UFH is the preferred agent for VTE prophylaxis in patients with severe renal dysfunction (creatinine clearance < 30 mL/min) because the liver is the main site of heparin biotransformation, making UFH safer in patients with renal failure, as stated by the National Comprehensive Cancer Network and the American College of Cardiology 1, 2
• UFH is preferred over LMWH in this population, according to the National Comprehensive Cancer Network 2

Administration and Timing

• First prophylactic UFH dose should be administered no sooner than 1 hour after needle/catheter placement, as recommended by the American Society of Clinical Oncology 3
• In patients receiving preoperative prophylactic UFH, neuraxial puncture/catheter manipulation or removal should not occur within 4-6 hours after UFH administration, according to the American Society of Clinical Oncology 3
• Subsequent UFH administration may occur no earlier than 1 hour after catheter removal, as recommended by the American Society of Clinical Oncology 3

Duration of Prophylaxis

• For medical patients: Continue for the length of hospital stay or until fully ambulatory, as recommended by the American Society of Clinical Oncology 3
• For surgical patients: Continue for at least 7-10 days, according to the American Society of Clinical Oncology 3
• Extended prophylaxis for up to 4 weeks should be considered for high-risk patients, such as those undergoing high-risk cancer surgery, as recommended by the American Society of Clinical Oncology and supported by the American College of Cardiology 5, 3

Contraindications and Alternatives

• UFH is contraindicated in patients with heparin-induced thrombocytopenia (HIT), as stated by the National Comprehensive Cancer Network and the American College of Cardiology 1, 2
• For patients with a history of HIT, consider alternatives such as direct thrombin inhibitors or fondaparinux, as recommended by the American College of Cardiology 1
• For patients at high risk for major bleeding complications, consider intermittent pneumatic compression (IPC) devices, as recommended by the American College of Cardiology 5
• Mechanical methods should be added to pharmacological prophylaxis rather than used as monotherapy unless pharmacological prophylaxis is contraindicated, according to the American College of Cardiology 5, 6

Monitoring

• Routine coagulation monitoring is generally not necessary for prophylactic doses of UFH, although this statement is not supported by a citation in the provided text.